PointClickCare vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud-based EHR and care coordination platform for long-term and post-acute care organizations. Mississauga, Canada. Raised $172M+, unicorn. Serves 27,000+ care facilities across North America.
About
PointClickCare is North America's leading cloud-based software platform for the long-term and post-acute care (LTPAC) market, headquartered in Mississauga, Ontario, Canada. Founded in 1999, the company has raised over $172 million and achieved unicorn valuation status. PointClickCare serves over 27,000 care facilities including skilled nursing facilities, senior living communities, assisted living centers, and home health agencies across the United States and Canada. The platform provides electronic health records (EHR), billing, care coordination, and business intelligence capabilities.\n\nPointClickCare's platform is built around the complex clinical and regulatory workflows unique to post-acute care, which differ substantially from acute hospital EHR requirements. The system manages MDS assessments, care planning, medication administration records, therapy documentation, and the complex billing requirements for Medicare, Medicaid, and managed care payers. Its network effect is significant — because PointClickCare connects so many facilities, care transitions between hospitals and post-acute settings can be managed with streamlined data exchange.\n\nThe company has expanded through strategic acquisitions including Collective Medical, which added care transition and high-risk patient identification capabilities powered by a large hospital and payer data network. PointClickCare's Marketplace ecosystem allows third-party technology vendors to integrate with the platform, creating an app store model that extends its functionality without requiring PointClickCare to build every adjacent capability. As value-based care models push accountable care organizations to manage patient outcomes across the full episode of care, PointClickCare's position at the post-acute node of the care continuum becomes increasingly strategically important.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.